News for BioCryst Pharmaceuticals, Inc. (BCRX)

Summary BioCryst Pharmaceuticals Inc (BCRX), a global biotechnology company specializing in treatments for rare diseases, announced on July 21, 2025, that it wi

RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. ( BCRX) today announced that the company will report its second

- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases -

BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 7, RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) and set a price target of $13.00. The same day, the company also announced the appointment of Babar Ghias as Chief Financial Officer and […]

Summary BioCryst Pharmaceuticals Inc (BCRX) announced on July 9, 2025, that it will present new research findings at the 2025 US HAEA National Summit in Baltimo

Summary BioCryst Pharmaceuticals Inc (BCRX), a global biotechnology company, announced on July 7, 2025, the appointment of Babar Ghias as the new Chief Financia

RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. ( BCRX) today announced the appointment of Babar Ghias as chie

Key Highlights: Babar Ghias appointed as CFO at BioCryst Pharmaceuticals (BCRX), bringing extensive experience from AvenCell Therapeutics. Analyst consen

BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) is one of the best high short interest stocks with huge upside potential. On June 27, BioCryst Pharmaceuticals announced a definitive agreement to sell its European ORLADEYO (berotralstat) business to Neopharmed Gentili for a total consideration of up to $264 million. The amount includes an upfront payment of $250 million for […]

Summary On July 3, 2025, BioCryst Pharmaceuticals Inc (BCRX), a global biotechnology company, announced the grant of restricted stock units (RSUs) to eight newl

BioCryst Pharmaceuticals (BCRX) has granted restricted stock units (RSUs) to eight new employees. The RSUs cover a total of 57,000 shares of common stock, v

RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees restricted stock units (RSUs) covering an aggregate of 57,000 shares of BioCryst common stock. The RSUs were granted as of July 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

””Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestonesâ

BioCryst Pharmaceuticals (BCRX) has revised its financial forecast, projecting to conclude 2027 with around $700 million in cash and free of term debt. This upd

BioCryst Pharmaceuticals (BCRX) to sell its European ORLADEYO® business for up to $264 million. The transaction will eliminate $249 million in debt, saving

BioCryst Pharmaceuticals (BCRX) has unveiled promising findings regarding ORLADEYO's long-term effectiveness and safety for the preventative treatment of heredi

””Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile”” ””Patient

**media[653950]**

BioCryst Pharmaceuticals (BCRX) has achieved a significant milestone with the approval of ORLADEYO for routine prevention of hereditary angioedema (HAE) attacks